98%
921
2 minutes
20
Background: COVID-19 vaccination has significantly reduced the risk of severe disease. Yet, across many settings in Australia, there have been issues with equitable uptake, particularly for some people from ethnic minority backgrounds. To bridge this gap, training workshops were held to support the capacity of local community leaders to communicate about the COVID-19 booster vaccines and other recommended vaccines as local vaccine champions. This study aimed to explore participants' vaccine and communication knowledge and the acceptability and perceived usefulness of the Vaccine Champions Program.
Methods: The training included information about eligibility for the COVID-19 booster vaccines and the rationale for their continued use, information about other vaccines recommended for adults, as well as recommended travel vaccines. Fifteen in-depth interviews were conducted from July to December 2023. Attendees of the workshop were purposefully selected to identify as leaders of multicultural communities in Sydney, with expressions of interest being offered to all attendees to participate in the evaluation of the workshop through a semi structured interview. They contributed their insights on the development and implementation of the training workshop sessions, participants' views on becoming vaccine champions, and the improvements needed for future sessions.
Results: Interviewees emphasised the importance of providing reliable information in the training to address vaccine hesitancy. They highlighted the significance of the training in boosting their confidence to promote and champion vaccination within their community, and suggested incorporating personal stories, testimonies, and interactive elements to enhance the training package. They expressed positive views on the program's continuation beyond the COVID-19 pandemic, emphasising the importance of their knowledge of vaccines remaining current with research and adapting communication approaches.
Conclusion: Continued collaboration between community leaders and healthcare providers, ongoing training, and staying current with research are essential for ensuring the program's long-term sustainability, self-efficacy, and impact on public health outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2025.127629 | DOI Listing |
Gynecol Oncol
August 2025
Department of Oncology, Johns Hopkins School of Medicine; Baltimore, MD, USA; Department of Gynecology/Obstetrics, Johns Hopkins School of Medicine; Baltimore, MD, USA; Department of Pathology, Johns Hopkins School of Medicine; Baltimore, MD, USA. Electronic address:
Objective: Since anti-tumor immunity is enhanced by vaccination of mice adjacent to human papillomavirus type 16 (HPV16+) tumors, we examined whether HPV16 L2E7E6 fusion protein (TA-CIN) vaccination in the thigh of HPV16+ cervical cancer patients would be more immunogenic than their arm.
Methods: HPV16+ cervical cancer (stage IB1-IVA) patients, who had completed standard-of-care treatment within the past year and absent evidence of disease (NED), were enrolled in a pilot study (NCT02405221). Participants were randomized 1:1 to receive three 100 μg TA-CIN monthly intramuscular immunizations either in the arm or thigh and followed for two years for safety (CTCAEv4.
Vaccine
August 2025
School of Population Health, Faculty of Medicine and Health, University of New South Wales, NSW, Australia.
Background: COVID-19 vaccination has significantly reduced the risk of severe disease. Yet, across many settings in Australia, there have been issues with equitable uptake, particularly for some people from ethnic minority backgrounds. To bridge this gap, training workshops were held to support the capacity of local community leaders to communicate about the COVID-19 booster vaccines and other recommended vaccines as local vaccine champions.
View Article and Find Full Text PDFHealthc Q
May 2025
Nasma Ashraf, is a project coordinator at HCSL, Toronto, ON, who applies her experience in health promotion and chronic disease prevention in newcomer and marginalized communities to support innovative, community-led solutions to improve health.
The COVID-19 pandemic revealed profound inequities in the health of Canadians: racially diverse, newcomer and low-income communities were most likely to experience illness and death. In December 2020, Ontario announced the High Priority Communities Strategy (HPCS) that funded "lead agencies" in 17 marginalized communities to support scores of community partners who in turn devised culturally appropriate "micro-strategies" to provide education, tests, vaccinations and wrap-around care. We draw on evaluations conducted over three years to assess the HPCS and synthesize lessons learned for integrating care, reducing health inequities and improving population health from the "ground up.
View Article and Find Full Text PDFTrends Microbiol
July 2025
SAMRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; Centre for the AIDS Programme of Research in South Africa, Dur
The Global Immunology and Immune Sequencing for Epidemic Response (GIISER) network, established in 2021, exemplifies the power of South-South collaboration in pandemic preparedness and response. Emerging from the COVID-19 crisis, GIISER integrated genomic surveillance, immunology, and capacity building across African, Asian, and South American sites, enabling rapid detection and characterization of SARS-CoV-2 variants. Through technology transfer, standardized protocols, and coordinated training, GIISER informed public health policy, advanced monoclonal antibody discovery, and strengthened local expertise.
View Article and Find Full Text PDFLancet Public Health
August 2025
The Migrant Health Research Group, Institute for Infection and Immunity, School of Health and Medical Sciences, City St George's, University of London, London, UK. Electronic address:
Background: WHO's Cervical Cancer Elimination Initiative has set a target for 90% of girls to be fully vaccinated against human papillomavirus (HPV) by the age of 15 years by 2030, to substantially reduce deaths from cervical and other HPV-related cancers. However, progress has been slow, with only 27% global vaccine coverage in 2023. Migrants are an under-immunised group globally for many vaccine-preventable diseases, with data showing that they experience a high burden of HPV infection and widespread HPV under-immunisation.
View Article and Find Full Text PDF